These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35982823)

  • 41. Insights into development of Decaprenyl-phosphoryl-β-D-ribose 2'-epimerase (DprE1) inhibitors as antitubercular agents: A state of the art review.
    Bonde C; Gawad J; Bonde S
    Indian J Tuberc; 2022 Oct; 69(4):404-420. PubMed ID: 36460369
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting decaprenylphosphoryl-β-D-ribose 2'-epimerase for Innovative Drug Development Against Mycobacterium Tuberculosis Drug-Resistant Strains.
    El Haddoumi G; Mansouri M; Kourou J; Belyamani L; Ibrahimi A; Kandoussi I
    Bioinform Biol Insights; 2024; 18():11779322241257039. PubMed ID: 38812740
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery of novel DprE1 inhibitors via computational bioactivity fingerprints and structure-based virtual screening.
    Hu XP; Yang L; Chai X; Lei YX; Alam MS; Liu L; Shen C; Jiang DJ; Wang Z; Liu ZY; Xu L; Wan KL; Zhang TY; Yin YL; Li D; Cao DS; Hou TJ
    Acta Pharmacol Sin; 2022 Jun; 43(6):1605-1615. PubMed ID: 34667293
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.
    Lv K; You X; Wang B; Wei Z; Chai Y; Wang B; Wang A; Huang G; Liu M; Lu Y
    ACS Med Chem Lett; 2017 Jun; 8(6):636-641. PubMed ID: 28626525
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthesis, Activity, Toxicity, and In Silico Studies of New Antimycobacterial
    Pais JP; Antoniuk O; Pires D; Delgado T; Fortuna A; Costa PJ; Anes E; Constantino L
    Pharmaceuticals (Basel); 2024 May; 17(5):. PubMed ID: 38794178
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity.
    Panda M; Ramachandran S; Ramachandran V; Shirude PS; Humnabadkar V; Nagalapur K; Sharma S; Kaur P; Guptha S; Narayan A; Mahadevaswamy J; Ambady A; Hegde N; Rudrapatna SS; Hosagrahara VP; Sambandamurthy VK; Raichurkar A
    J Med Chem; 2014 Jun; 57(11):4761-71. PubMed ID: 24818517
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidase.
    Landge S; Mullick AB; Nagalapur K; Neres J; Subbulakshmi V; Murugan K; Ghosh A; Sadler C; Fellows MD; Humnabadkar V; Mahadevaswamy J; Vachaspati P; Sharma S; Kaur P; Mallya M; Rudrapatna S; Awasthy D; Sambandamurthy VK; Pojer F; Cole ST; Balganesh TS; Ugarkar BG; Balasubramanian V; Bandodkar BS; Panda M; Ramachandran V
    Bioorg Med Chem; 2015 Dec; 23(24):7694-710. PubMed ID: 26643218
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Benzothiazinones mediate killing of Corynebacterineae by blocking decaprenyl phosphate recycling involved in cell wall biosynthesis.
    Grover S; Alderwick LJ; Mishra AK; Krumbach K; Marienhagen J; Eggeling L; Bhatt A; Besra GS
    J Biol Chem; 2014 Feb; 289(9):6177-87. PubMed ID: 24446451
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design, Synthesis, Antimycobacterial Evaluation, and In Silico Studies of 3-(Phenylcarbamoyl)-pyrazine-2-carboxylic Acids.
    Semelková L; Janošcová P; Fernandes C; Bouz G; Janďourek O; Konečná K; Paterová P; Navrátilová L; Kuneš J; Doležal M; Zitko J
    Molecules; 2017 Sep; 22(9):. PubMed ID: 28880230
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthetic molecules as DprE1 inhibitors: A patent review.
    Imran M; A S A; Thabet HK; Abida ; Afroz Bakht M
    Expert Opin Ther Pat; 2021 Aug; 31(8):759-772. PubMed ID: 33709862
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structural studies of Mycobacterium tuberculosis DprE1 interacting with its inhibitors.
    Piton J; Foo CS; Cole ST
    Drug Discov Today; 2017 Mar; 22(3):526-533. PubMed ID: 27666194
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity.
    Naik M; Humnabadkar V; Tantry SJ; Panda M; Narayan A; Guptha S; Panduga V; Manjrekar P; Jena LK; Koushik K; Shanbhag G; Jatheendranath S; Manjunatha MR; Gorai G; Bathula C; Rudrapatna S; Achar V; Sharma S; Ambady A; Hegde N; Mahadevaswamy J; Kaur P; Sambandamurthy VK; Awasthy D; Narayan C; Ravishankar S; Madhavapeddi P; Reddy J; Prabhakar K; Saralaya R; Chatterji M; Whiteaker J; McLaughlin B; Chiarelli LR; Riccardi G; Pasca MR; Binda C; Neres J; Dhar N; Signorino-Gelo F; McKinney JD; Ramachandran V; Shandil R; Tommasi R; Iyer PS; Narayanan S; Hosagrahara V; Kavanagh S; Dinesh N; Ghorpade SR
    J Med Chem; 2014 Jun; 57(12):5419-34. PubMed ID: 24871036
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Virtual screening and free energy estimation for identifying Mycobacterium tuberculosis flavoenzyme DprE1 inhibitors.
    Niranjan Kumar ; Srivastava R; Prakash A; Lynn AM
    J Mol Graph Model; 2021 Jan; 102():107770. PubMed ID: 33065513
    [TBL] [Abstract][Full Text] [Related]  

  • 54. QSAR Studies, Molecular Docking, Molecular Dynamics, Synthesis, and Biological Evaluation of Novel Quinolinone-Based Thiosemicarbazones against
    Valencia J; Rubio V; Puerto G; Vasquez L; Bernal A; Mora JR; Cuesta SA; Paz JL; Insuasty B; Abonia R; Quiroga J; Insuasty A; Coneo A; Vidal O; Márquez E; Insuasty D
    Antibiotics (Basel); 2022 Dec; 12(1):. PubMed ID: 36671262
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of selective DprE1 inhibitors: Design, synthesis, crystal structure and antitubercular activity of benzothiazolylpyrimidine-5-carboxamides.
    Chikhale R; Menghani S; Babu R; Bansode R; Bhargavi G; Karodia N; Rajasekharan MV; Paradkar A; Khedekar P
    Eur J Med Chem; 2015; 96():30-46. PubMed ID: 25874329
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Side Chain-Modified Benzothiazinone Derivatives with Anti-Mycobacterial Activity.
    Fan D; Wang B; Stelitano G; Savková K; Riabova O; Shi R; Wu X; Chiarelli LR; Mikušová K; Makarov V; Lu Y; Hong Y; Qiao C
    Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509615
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structure-Based Drug Design and Characterization of Sulfonyl-Piperazine Benzothiazinone Inhibitors of DprE1 from Mycobacterium tuberculosis.
    Piton J; Vocat A; Lupien A; Foo CS; Riabova O; Makarov V; Cole ST
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012754
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosis.
    Gao C; Peng C; Shi Y; You X; Ran K; Xiong L; Ye TH; Zhang L; Wang N; Zhu Y; Liu K; Zuo W; Yu L; Wei Y
    Sci Rep; 2016 Jul; 6():29717. PubMed ID: 27405961
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Crystal structure of decaprenylphosphoryl-β- D-ribose 2'-epimerase from Mycobacterium smegmatis.
    Li H; Jogl G
    Proteins; 2013 Mar; 81(3):538-43. PubMed ID: 23184707
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis.
    Chikhale RV; Barmade MA; Murumkar PR; Yadav MR
    J Med Chem; 2018 Oct; 61(19):8563-8593. PubMed ID: 29851474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.